According to GlobalData’s medical device pipeline database, 26 Gadolinium-Based MRI Contrast Agents devices are in various stages of development globally. GlobalData’s report provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.

Smarter leaders trust GlobalData

Of these devices, 13 are in active development, while the remaining 13 are in an inactive stage of development. There are eight products in the early stages of development, and the remaining five are in the late stages of development.

Gadolinium-Based MRI Contrast Agents are composed of gadolinium (Gd). Gd, which has a variety of complexes, it is used due to its ability to exhibit a strong paramagnetic effect, a result of its 7 unpaired electrons. Gadolinium-based contrast can be used to enhance both T1 and T2 images, depending on the concentration in which it is used. For this market, these agents are the structurally linear gadolinium-based contrast agents, which have been found to deposit Gd in the brain after use. Brands include Omniscan and Multihance.

Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.

Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Gadolinium-Based MRI Contrast Agents pipeline devices are all expected to be approved within the next ten years.

Currently, private organizations, public entities and institutions are working on the development of Gadolinium-Based MRI Contrast Agents devices. Overall, most of these Gadolinium-Based MRI Contrast Agents pipeline devices are being developed by private entities.

Key players involved in the active development of Gadolinium-Based MRI Contrast Agents include Inlighta Biosciences, Iowa State University, Knowledgepie, Lantheus Medical Imaging, Molecular Theranostics, Nanosion, Northwestern University, Signablok, University of Arizona and University of Chicago.

For a complete picture of the developmental pipeline for Gadolinium-Based MRI Contrast Agents devices, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.